Bowel Cancer Australia was named Best Small Charity of the Year 2019 at the national Third Sector Awards, held in Sydney Tuesday night, in recognition of our contribution to the third sector in a meaningful and impactful way that produces measurable benefits.

Today is World Metastatic Colorectal Cancer Day, a day dedicated to raising awareness about the most advanced form of bowel cancer, also known as metastatic colorectal cancer or mCRC.
 

Many find daily physical activity a chore, despite evidence that exercise can reduce bowel cancer risk and is essential during and after any cancer treatment, to assist in managing side effects and improve quality of life.

A new study has revealed that being active at a young age can reduce the risk of developing bowel cancer later in life, and active adolescents who remain active as adults reduce their bowel cancer risk even more.

Bowel Cancer Australia is very excited to announce that we have been nominated for the best small charity of the year in the Third Sector Awards 2019, celebrating Australia’s most notable leaders and organisations that are making a difference.

Sam Fitzpatrick just finished 18-months of grueling treatment sessions following a Stage IV bowel cancer diagnosis at the age of 33.

But he would tell you he’s lucky.

Bowel Cancer Australia today released initial findings from the first national My Colonoscopy Experience questionnaire. The questionnaire opened in September 2018 at the same time as the Colonoscopy Clinical Care Standard, created by the Australian Commission on Safety and Quality in Health Care (ACSQHC).

Australia's Therapeutic Goods Administration (TGA) has today given Keytruda® (pembrolizumab) provisional approval for patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) bowel cancer.

In the first week of Bowel Cancer Awareness Month 2019, the University of Sydney officially opened the Kolling Institute node of their Sydney Mass Spectrometry core facility. The facility was made possible with a significant financial gift of $500,000 from Bowel Cancer Australia, established to support the research of the Lawrence Penn Chair of Bowel Cancer Research, Professor Mark Molloy PhD and his research team.